Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 1/20 | 0.35 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.35 |
| ▸ | BCR | P11274 | 1/20 | 0.35 |
| ▸ | F10 | P00742 | 2/20 | 0.34 |
| ▸ | F9 | P00740 | 1/20 | 0.34 |
| ▸ | PRSS1 | P07477 | 8/20 | 0.34 |
| ▸ | TMPRSS2 | O15393 | 1/20 | 0.34 |
| ▸ | PLAU | P00749 | 2/20 | 0.34 |
| ▸ | F2 | P00734 | 2/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.33 |
| ▸ | ST14 | Q9Y5Y6 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16419763 | 0.94 | F9 (0.32) | ABL1ABCB1BCRF10F9 | |
| SCHEMBL15037015 | 0.86 | PRSS1 (0.42) | F10PRSS1F2L3MBTL1 | |
| SCHEMBL16419773 | 0.82 | L3MBTL1 (0.43) | F10PRSS1F2L3MBTL1 | |
| SCHEMBL15805867 | 0.82 | F9 (0.36) | F10F9PRSS1TMPRSS2 | |
| SCHEMBL15036995 | 0.81 | PRSS1 (0.38) | F10PRSS1F2L3MBTL1 | |
| SCHEMBL16419736 | 0.80 | L3MBTL1 (0.40) | F10PRSS1L3MBTL1 | |
| SCHEMBL15139164 | 0.79 | ICMT (0.33) | F10 | |
| SCHEMBL16169694 | 0.77 | F9 (0.34) | F10F9L3MBTL1 | |
| SCHEMBL16419740 | 0.76 | L3MBTL1 (0.45) | F10PRSS1F2L3MBTL1 | |
| SCHEMBL16419772 | 0.76 | CSF3R (0.42) | ABL1ABCB1BCR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9469616-B2 | Cyclic compounds and methods of making and using the same | CELLCEUTIX CORPORATION (US) | 2016-10-18 | — | — | US | disclosed |
| US-20150031738-A1 | CYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | UNIVERSITY OF MASSACHUSETTS (US) | 2015-01-29 | — | — | US | disclosed |
| US-20150031738-A1 | CYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | UNIVERSITY OF MASSACHUSETTS (US) | 2015-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150031738-A1 | CYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | MUC1, TLR3, ALG1 | ABL1 4833/4885ABCB1 4096/4885BCR 3629/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.